A reverse hemagglutination assay was used to study adherence to human erythrocytes by Escherichia coli H10407, which possesses colonization factor antigen I. Pretreatment of erythrocytes with trypsin, chymotrypsin, papain, protease, and neuraminidase completely abolished attachment reactivity. In addition, the hemagglutination reaction was prevented by the presence of urea and guanidine. In contrast, the lipases, nucleotide hydrolases, exoglycosidases, and reagents affecting disulfide or sulfhydryl moieties did not alter receptor reactivity. Glycoconjugates containing sialic acid inhibited the hemagglutination reaction. Furthermore, a sialoglycoprotein isolated from the erythrocyte membrane inhibited the hemagglutination reaction. Collectively, these data indicate that the erythrocyte receptor responsible for attachment by E. coli possessing colonization factor antigen I is a sialoglycoconjugate.
It is now generally accepted that attachment of an organism to a host tissue cell is a prerequisite for bacterial colonization and subsequent development of disease (16) . The available data support the hypothesis than an organism must possess a specific adhesin which permits binding to a specific host tissue cell receptor (16) . For human enterotoxigenic Escherichia coli (ETEC), one of the colonizing adhesins that has been described is colonizing factor antigen I (CFA-I) (7) . The role of CFA-I in facilitating attachment of human ETEC as an initial step in the pathogenesis of disease has been clearly established (6) .
The early pioneering work on bacterial adhesins has been followed by intensive investigations to define the receptors involved in attachment. Gibbons (10) found the strongest inhibitors of E. coli K88 mannose-resistant hemagglutination (MRHA) to be glycoconjugates containing D-galactose. They concluded that D-galactose is involved in the receptor but could not define the receptor. Kallenius et al. (14) have shown that the hemagglutination receptor for E. coli associated with urinary tract infections is the pK antigen.
The studies reported here were conducted to help define the nature of the hemagglutinin receptor in order to determine the feasibility of synthesizing a compound that could competitively inhibit CFA-I attachment and subsequent disease. Although the disease state occurs in the gastrointestinal tract, human erythrocytes (RBCs) were chosen as a study model because (i) the phenomena of MRHA of RBCs and virulence attachment ability are both directly correlated to the CFA-I adhesin (4), (ii) human RBCs are much easier to obtain and maintain than are human gut sections, and (iii) RBCs DE 19711. believe that the results of these preliminary studies suggest a complex receptor containing carbohydrates that would limit the chances of development of a commercial competitor.
MATERIALS AND METHODS
Organism. ETEC strain H10407 (078:H11), possessing CFA-I, was grown on colonization factor antigen medium as described by Evans et al. (5) , harvested as previously described (11) , and frozen in low ionic medium (20) at a concentration of 1.33 x 1010 organisms per ml. For the attachment studies, a frozen ampule was thawed and diluted in low ionic medium to contain 7.5 x 109 organisms per ml.
RBC preparation. Human citrated type A+ blood was purchased from Community Blood and Plasma Service, Folcroft, Pa., and processed as previously described (21) . For determination of the effect of the selected reagents on RBC receptor reactivity, a suspension containing 1.2 x 109 RBCs per ml was prepared in the diluent required by the respective reagents.
Chemicals used to determine effect on the RBC hemagglutinin receptor. The reagents (Table 1) phosphodiesterase, and alkaline phosphatase (2,400 U/ml) did not alter the receptor reactivity (data not shown). Similarly, negative results were obtained when RBCs were pretreated at 2,000 U/ml for 24 h with a-amylase, P-amylase, amyloglucosidase, cX-L-fucosidase, 3-galactosidase, aglucosidase, or hyaluronidase (data not shown). In sharp contrast, neuraminidase at 0.25 U/ml completely destroyed receptor reactivity within 1 h (Table 2) . Reduction in receptor reactivity was also noted after pretreatment with periodic acid; however, p-hydroxymercuribenzoate, which oxidizes sulfhydryl groups, and sodium sulfite and dithiothreitol, each capable of splitting disulfide bonds, did not alter receptor reactivity (Table 3) .
For determination of the effect of the selected chemicals on the interaction between RBCs and CFA-I ETEC, equal volumes of the RBC-chemical suspension and CFA-I ETEC were mixed and observed microscopically for MRHA complexing. To preclude nonspecific autoagglutination by the chemical, we included a control consisting of a mixture of the respective chemical and RBC without CFA-I ETEC. Sodium sulfite, L-cysteine hydrochloride, dithiothreitol, and p-hydroxymercuribenzoate did not prevent the formation of RBC-bacteria complexes, suggesting that disulfide and sulphhydryl bonding are not required. Conversely, urea and guanidine hydrochloride prevented the foirmation of the RBC-bacteria complexes. The effect produced by urea and guanidine hydrochloride was reversible, suggesting that hydrogen bonding is involved in the formation of the RBC-bacteria MRHA complexes (Table 4) . N-Acetylneuraminic acid (sialic acid), a sialoglycoprotein, ganglioside type II, and mucin type II, all of which contain sialic acid, were able to inhibit CFA-I hemagglutination. Conversely, lipids and selected carbohydrates had no effect (Table 5) . DISCUSSION These studies were undertaken to provide some insight into the RBC receptor involved in CFA-I ETEC attachment and subsequent MRHA. The use of enzymes of known substrate specificities and chemicals of defined compositions has long provided an initial approach for obtaining prelimi- nary evidence of the chemical compositions of receptors (12) . When possible, the enzymes were initially employed at 1 mg/ml and a dose-response test was performed to determine the minimum number of units per milliliter required to inactivate the receptor within 1 h. However, many of the chromatography-purified enzymes were available only in limited quantities. In such cases, the enzymes were employed at the highest available concentration and incubated for a minimum of 24 h. RBC treatment with a-chymotrypsin, papain, protease, thermolysin, and trypsin completely destroyed RBC binding capacity for CFA-I adhesin, suggesting that a protein moiety may be involved ( Table 2 ). The possibility that these peptide hydrolases have adsorbed to the surface and inhibited CFA-I attachment by sterically inhibiting in a nonspecific manner cannot be excluded. However, other peptide hydrolases, many of the glycosidases as well as a variety of ester hydrolases, and nucleotide hydrolases did not alter the ability of the RBCs to bind CFA-I.
The reduction in RBC reactivity by periodic acid suggests that the receptor may contain a carbohydrate moiety (Table  3) . Further implication of carbohydrate involvement was evidenced by the complete loss of RBC reactivity after treatment with neuraminidase ( Table 2 ). The cleavage of sialic acid residues by neuraminidase proceeds with extremely high specificity (3). Hence, this result implies that the receptor domain miay contain a sialoconjugate. Of course, it is possible that the receptor is bound to a component removed by the proteases or neuraminic acid, which would reduce RBC receptor reactivity in a nonspecific manner. Therefore, on the basis of results of the enzyme studies, we examined the ability of selected reagents to competitively inhibit CFA-I attachment ( Table 5) . None of the agents that lacked sialic acid inhibited CFA-I attachment. Conversely, agents that did contain sialic acid were able to inhibit CFA-I attachment. These findings are in agreement with those of Bergman et al. (2) , who found that sialic acid can inhibit CFA-I attachment, as well as those of Faris et al. (8) , who found that sialogangliosides can inhibit the MRHA reaction of CFA-I.
The RBC membrane has been one of the most frequently studied mammalian membranes, and there is extensive data available relating to its characterized components. Results of the elaborate work carried out by Marchesi et al. (17, 19) suggest that the only characterized RBC membrane component which is sensitive to both peptide hydrolases and neuraminic acid is glycophorin, a sialoglycoprotein. A sialoconjugate isolated from the RBC membrane by the procedure of Marchesi (17) as modified by Furthmayr (9) was VOL. 21, 1985 on July 3, 2017 by guest http://jcm.asm.org/ Downloaded from found to inhibit the MRHA of CFA-I (Table 5 ). The data, demonstrating that the sialoglycoprotein fraction is eight times more active than sialic acid, is intriguing. Glycophorin is also reputed to be a receptor for influenza virus (13) and mycoplasmas (1) . However, any alteration of the molecule to determine the minimal unit required for binding has resulted in a drastically decreased binding capacity (23) .
Collectively, these studies suggest that the RBC receptor for CFA-I is a sialoglycoconjugate since: (i) RBC reactivity was reduced after treatment with periodic acid and neuraminidase, (ii) CFA-I MRHA was inhibited by compounds containing sialic acid, and (iii) a sialoglycoconjugate isolated from the RBC membrane inhibited CFA-I MRHA attachment.
